Denali Therapeutics. has filed a patent for solid forms of a specific compound, along with the process of preparation, pharmaceutical compositions, and methods of use. Claim 1 has been canceled. GlobalData’s report on Denali Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Denali Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Denali Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Denali Therapeutics's grant share as of January 2024 was 16%. Grant share is based on the ratio of number of grants to total number of patents.

Solid forms of pharmaceutical compound for medical use

Source: United States Patent and Trademark Office (USPTO). Credit: Denali Therapeutics Inc

The patent application (Publication Number: US20240025915A1) describes a solid form of 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5-dihydro-2H-pyrido[3,4-f][1,4]oxazepine-9-carbonitrile, known as crystalline Form A. This solid form is characterized by its crystallinity, with at least 50% being crystalline, and specific X-ray powder diffraction patterns with distinct peaks at various 2-theta degrees. Additionally, the solid form exhibits unique thermal properties as evidenced by its differential scanning calorimetry (DSC) curve and DSC/TGA profile.

Furthermore, the patent application includes claims related to the pharmaceutical composition containing the solid form of claim 2 and a pharmaceutically acceptable carrier. It also outlines a method for treating diseases and conditions mediated by RIPK1 by administering the solid form of claim 2 to patients in need. These claims highlight the potential therapeutic applications of the described solid form in addressing specific medical conditions. The patent application provides detailed characterization and specifications for the solid form, emphasizing its unique properties and potential benefits in pharmaceutical formulations for treating relevant diseases and conditions.

To know more about GlobalData’s detailed insights on Denali Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies